Skip to main content
Clinical Trials/ISRCTN25526593
ISRCTN25526593RecruitingNot Applicable

eurofeedback for Cannabis Use Disorder: a pilot study on clinical effects and possible relationship with brain dopamine function

Geneva University Hospitals - Addiction Unit0 sites51 target enrollmentStarted: December 1, 2017Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
51

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. 34 patients with DSM-5 Diagnosis of Cannabis Use Disorder (CUD)
  • 2. 17 sex and age-matched healthy controls
  • 3. Aged between 18 and 50 years inclusive
  • 4. Informed consent
  • 5. Available to complete the study
  • 6. Negative serum pregnancy test at screening (for women of childbearing potential)

Exclusion Criteria

  • 1. Psychiatric disorder (other than CUD in CUD patients)
  • 2. Neurological disorder
  • 3. Significant medical condition such as cancer, liver disease, hepatic impairment, renal disease, neuroleptic malignant syndrome, non-traumatic rhabdomyolysis, pheochromocytoma, or glaucoma
  • 4. Current treatment with antipsychotic or benzodiazepine or monoamine oxidase inhibitor
  • 5. Metal implant
  • 6. Participation in a research/clinical study involving radiation exposure in the past 12 months
  • 7. Pregnancy
  • 8. Breastfeeding
  • 9. Lack of safe contraception

Investigators

Sponsor
Geneva University Hospitals - Addiction Unit

Similar Trials